腺A受体介导的阳性异质机制
Christopher J Draper-Joyce1,2, Rebecca Bhola3, Jinan Wang4
1Drug Discovery Biology and Department of Pharmacology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
Nature
|September 9, 2021
概括
这项研究引入了MIPS521,一种新的腺素A1受体 (A1R) 调节剂,在老鼠中显示出有效的非阿片类疼痛缓解. 它强调了开发针对性神经病痛治疗的新策略.
科学领域:
- 药理学
- 神经科学
- 结构生物学
背景情况:
- 腺A1受体 (A1R) 是治疗神经病痛的非阿片类止痛药的潜在点.
- 由于选择性差和副作用,先前使用正性A1R激动剂的尝试失败了.
研究的目的:
- 为了研究MIPS521作为A1R的阳性异质调节剂,用于神经性疼痛的止痛效果.
- 通过MIPS521阐明A1R调制的结构基础.
主要方法:
- 在神经性疼痛的小鼠模型中进行体内止痛疗效测试.
- 用X射线结晶学来确定A1R-腺-MIPS521-Gi2复合物的结构.
- 分子动力学模拟和运动结合实验.
主要成果:
- 通过调节内源性腺水平,MIPS521在患有神经性疼痛的老鼠中显示出止痛效果.
- 晶体结构揭示了MIPS521的新结合点.
- 显示MIPS521可以稳定A1R- 氨酸- Gi2复合体.
结论:
- MIPS521代表了开发特定疾病背景的非阿片类止痛药的有希望的线索.
- 基于结构的异构药物设计提供了针对A1R的可行策略.
- 这项工作为未来开发A1R调节疼痛疗法提供了基础.
相关概念视频
Adrenergic Receptors: ɑ Subtype
2.3K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.3K
Analgesia and Pain Management
954
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
954
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.1K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.1K
Adrenergic Receptors (Adrenoceptors): Classification
3.7K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
3.7K
Adrenergic Agonists: Indirect-Acting Agents
2.1K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.1K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.2K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.2K


